Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
COL1A2
REST API REST API
Homo sapiens
COL1A2 is differentially expressed in 297 experiments: 198 organism parts: placenta, lung, ... (196 more);, 263 disease states: normal, glioblastoma, ... (261 more);, 111 cell types 351 cell lines 25 compound treatments and 72 other conditions.
Synonyms OI4
Orthologs Col1a2 (Mus musculus)   col1a2 (Danio rerio)   ENSCING00000006961 (Ciona intestinalis)   CO1A2_BOVIN (Bos taurus)   COL1A2 (Gallus gallus)   Col1a2 (Rattus norvegicus)   col1a2 (Xenopus laevis)   CO1A2_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, extracellular space, extracellular matrix structural constituent, transforming growth factor beta receptor signaling pathway, extracellular region, blood coagulation, Rho protein signal transduction, identical protein binding, axon guidance, SMAD binding, protein binding, bridging, extracellular matrix, collagen, collagen type I, leukocyte migration, collagen fibril organization, odontogenesis, blood vessel development, skeletal system development, protein heterotrimerization, regulation of blood pressure, platelet-derived growth factor binding, skin morphogenesis, platelet activation, cellular response to amino acid stimulus
InterPro Term Collagen, Fib_collagen_C
Gene-Disease Assocation OSTEOGENESIS IMPERFECTA, TYPE IV, OSTEOPOROSIS, EHLERS-DANLOS SYNDROME, TYPE VII, AUTOSOMAL DOMINANT, OSTEOGENESIS IMPERFECTA, TYPE I, EHLERS-DANLOS SYNDROME, AUTOSOMAL RECESSIVE, CARDIAC VALVULAR FORM, OSTEOGENESIS IMPERFECTA, TYPE III, OSTEOGENESIS IMPERFECTA, TYPE II
UniProt Accession A2TIK1, P08123, Q75N18, F5H299
Search EB-eye ENSG00000164692
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, ... (37 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-19397, E-GEOD-2450, ... (27 experiments)

Factor Value U/D Experiments
BT474
2
E-MEXP-440, E-MTAB-62
HCC38
2
E-MTAB-62, E-MTAB-37
SW480
2
E-MEXP-1014, E-MTAB-37
WI38
2
E-MTAB-37, E-MTAB-62
BC3
1
E-MTAB-37
GM00038C
1
E-GEOD-3860
345 more value(s).


Cell type

studied in E-GEOD-492, E-MEXP-1121, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, ... (51 experiments)

Factor Value U/D Experiments
stromal cell
1
5
E-MEXP-2034, E-GEOD-3998, E-GEOD-1460, E-MEXP-1327, E-GEOD-10797, ... (6 experiments)
CD8+ T cell
3
E-AFMX-5, E-GEOD-6740, E-MTAB-25
B cell
3
2
E-GEOD-3982, E-GEOD-13987
2
2
E-TABM-145, E-TABM-130
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
macrophage
1
E-GEOD-3982
105 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (75 experiments)

Factor Value U/D Experiments
glioblastoma
5
E-GEOD-4290, E-GEOD-6014, E-MTAB-37, E-MTAB-62, E-GEOD-4412 ... (5 experiments)
control
4
E-GEOD-3185, E-GEOD-20295, E-GEOD-16363, E-GEOD-20602
lung adenocarcinoma
4
E-MEXP-231, E-MTAB-37, E-GEOD-2514, E-MTAB-62
benign prostatic hyperplasia
3
E-GEOD-3868, E-MEXP-2034, E-MEXP-1243
gastric carcinoma
3
E-GEOD-2685, E-MTAB-37, E-GEOD-15460
prostate carcinoma
1
3
E-GEOD-96, E-GEOD-3868, E-MTAB-62, E-MEXP-2034
257 more value(s).


Compound treatment

studied in E-GEOD-697, E-GEOD-5824, E-GEOD-3720, E-TABM-868, E-GEOD-5099, ... (18 experiments)

Factor Value U/D Experiments
none
1
5
E-GEOD-5824, E-GEOD-2624, E-GEOD-412, E-TABM-868, E-GEOD-697, ... (6 experiments)
U0126
1
1
E-GEOD-697
dimethyl sulfoxide
1
E-GEOD-5824
AMP
1
1
E-MEXP-2285
unknown
1
E-GEOD-7307
lipopolysaccharide
1
E-TABM-868
19 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
86
1
1
E-GEOD-3494
86 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-2191, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-TABM-147, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-GEOD-7578, E-GEOD-20847, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-TABM-36, E-GEOD-17476, E-GEOD-21750, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5809, E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, ... (14 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-GEOD-20559, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-GEOD-10433, ... (32 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743, E-GEOD-5372

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-2487

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-1676, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Processing time: 0.33 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM